You are here

  • Home
  • Archive
  • Volume 79, Issue 11
  • Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?

Article metrics

Article menu

Download PDFPDF

Editorial
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
Free

 

Online download statistics by month:

Online download statistics by month: September 2020 to April 2025

AbstractFullPdf
Sep 2020444431207
Oct 2020670658275
Nov 202023723085
Dec 202013112161
Jan 2021999763
Feb 2021989827
Mar 2021858138
Apr 2021757429
May 2021747322
Jun 2021696819
Jul 2021555317
Aug 2021515024
Sep 2021615821
Oct 2021686525
Nov 2021504925
Dec 2021313110
Jan 2022858421
Feb 2022384114
Mar 2022505015
Apr 202234308
May 2022474524
Jun 2022414020
Jul 2022423712
Aug 202234323
Sep 2022373311
Oct 202280789
Nov 2022989811
Dec 202223236
Jan 202328268
Feb 202361556
Mar 202314142
Apr 2023111016
May 202325278
Jun 2023171511
Jul 2023232310
Aug 202314133
Sep 202313113
Oct 202331216
Nov 202322204
Dec 202323216
Jan 202410103
Feb 2024984
Mar 2024212114
Apr 202417179
May 202416152
Jun 202418157
Jul 202419188
Aug 2024211611
Sep 202415145
Oct 2024181410
Nov 202420218
Dec 202438385
Jan 202527246
Feb 2025464512
Mar 2025161210
Apr 2025111010
Total351133821309